While our findings support the prognostic value of TIGIT+PD-1+CXCL13+ CD8+ T cells within tumor tissues, future research should also explore non-invasive biomarkers—such as immune signatures detectable in peripheral blood—that could broaden the clinical utility and accessibility of immune monitoring for CRC patients. This evidence concerns the gene PDCD1 and colorectal carcinoma.